Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Daito Pharmaceutical Co., Ltd. ( (JP:4577) ) is now available.
Daito Pharmaceutical Co., Ltd. has revised its earnings forecast for the fiscal year ending May 31, 2025, due to lower than expected sales of high-value products and increased costs. Despite strong net sales, the company anticipates a decrease in operating, ordinary, and attributable profits, citing factors such as inventory valuation losses, higher outsourcing expenses, and increased R&D costs.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and production of pharmaceutical products. The company is listed on the Prime Market of the Tokyo Stock Exchange and is known for its efforts in producing both high-value and lower-margin pharmaceutical products.
YTD Price Performance: 1.96%
Average Trading Volume: 34,705
Technical Sentiment Signal: Hold
Current Market Cap: Yen32.7B
For detailed information about 4577 stock, go to TipRanks’ Stock Analysis page.